Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR2 | O95136 | 2/20 | 0.50 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.50 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.49 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.49 |
| ▸ | CNR2 | P34972 | 1/20 | 0.48 |
| ▸ | MMP2 | P08253 | 10/20 | 0.47 |
| ▸ | MMP3 | P08254 | 5/20 | 0.47 |
| ▸ | CETP | P11597 | 1/20 | 0.47 |
| ▸ | MMP1 | P03956 | 4/20 | 0.46 |
| ▸ | IL1RN | P18510 | 2/20 | 0.46 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.46 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27029539 | 1.00 | S1PR2 (0.50) | S1PR2S1PR1S1PR3CSNK1ECNR2 | |
| SCHEMBL4183117 | 0.98 | CNR2 (0.49) | S1PR2S1PR1S1PR3CSNK1ECNR2 | |
| SCHEMBL10436216 | 0.94 | CA1 (0.53) | CNR2MMP2MMP3IL1RNERAP2 | |
| SCHEMBL8905261 | 0.88 | MMP2 (0.55) | S1PR2S1PR1CNR2MMP2MMP3 | |
| SCHEMBL8905851 | 0.88 | MMP2 (0.55) | S1PR2S1PR1CNR2MMP2MMP3 | |
| SCHEMBL7077500 | 0.88 | MMP2 (0.55) | S1PR2S1PR1CNR2MMP2MMP3 | |
| SCHEMBL28210404 | 0.88 | MMP2 (0.55) | S1PR2S1PR1CNR2MMP2MMP3 | |
| SCHEMBL1716640 | 0.88 | MMP2 (0.55) | S1PR2S1PR1CNR2MMP2MMP3 | |
| SCHEMBL1285521 | 0.87 | ERAP1 (0.50) | IL1RNERAP2ERAP1 | |
| SCHEMBL26113257 | 0.87 | ESR1 (0.56) | S1PR2S1PR1S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230094176-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | CERENO SCIENT AB (SE) | 2023-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230094176-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | HDAC3, HDAC2, HDAC1 | S1PR2 1219/4885S1PR1 1543/4885S1PR3 1168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.